Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8829
|
pubmed:dateCreated |
1992-12-17
|
pubmed:abstractText |
An association between raised renin levels and myocardial infarction has been reported. We studied the effects of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, on the development of myocardial infarction and unstable angina in 6797 patients with ejection fractions < or = 0.35 enrolled into the two Studies of Left Ventricular Dysfunction (SOLVD) trials. Patients were randomly assigned to placebo (n = 3401) or enalapril (n = 3396) at doses of 2.5-20 mg per day in two concurrent double-blind trials with the same protocol. Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial (n = 4228). Follow-up averaged 40 months. In each trial there were significant reductions in the number of patients developing myocardial infarction (treatment trial: 158 placebo vs 127 enalapril, p < 0.02; prevention trial: 204 vs 161 p < 0.01) or unstable angina (240 vs 187 p < 0.001; 355 vs 312, p < 0.05). Combined, there were 362 placebo group patients with myocardial infarction compared with 288 in the enalapril group (risk reduction 23%, 95% CI 11-34%; p < 0.001). 595 placebo group patients developed unstable angina compared with 499 in the enalapril group (risk reduction 20%, 95% CI 9-29%, p < 0.001). There was also a reduction in cardiac deaths (711 placebo, 615 enalapril; p < 0.003), so that the reduction in the combined endpoint of deaths, myocardial infarction, and unstable angina was highly significant (20% risk reduction, 95% CI 14-26%; p < 0.0001). Enalapril treatment significantly reduced myocardial infarction, unstable angina, and cardiac mortality in patients with low ejection fractions.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1359258-1359265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1359258-1361633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1359258-1361634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1359258-1361635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1359258-1361636
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0140-6736
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
14
|
pubmed:volume |
340
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1173-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1359258-Angina, Unstable,
pubmed-meshheading:1359258-Blood Pressure,
pubmed-meshheading:1359258-Death, Sudden, Cardiac,
pubmed-meshheading:1359258-Enalapril,
pubmed-meshheading:1359258-Female,
pubmed-meshheading:1359258-Heart Failure,
pubmed-meshheading:1359258-Humans,
pubmed-meshheading:1359258-Incidence,
pubmed-meshheading:1359258-Male,
pubmed-meshheading:1359258-Myocardial Infarction,
pubmed-meshheading:1359258-Prognosis,
pubmed-meshheading:1359258-Prospective Studies,
pubmed-meshheading:1359258-Risk Factors,
pubmed-meshheading:1359258-Stroke Volume,
pubmed-meshheading:1359258-Time Factors
|
pubmed:year |
1992
|
pubmed:articleTitle |
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
|
pubmed:affiliation |
National Heart, Lung, and Blood Institute, Bethesda, Maryland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|